Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01222923 · ClinicalTrials.gov registry record · NA
Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fed Conditions
A NA study, sponsored by Ranbaxy Laboratories Limited.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT01222923: Completed NA study, sponsored by Ranbaxy Laboratories Limited.
NCT01222923 is a NA study that has completed, run by Ranbaxy Laboratories Limited. The registered enrollment target is 40 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01222923, a NA study, has completed, sponsored by Ranbaxy Laboratories Limited.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the pharmacokinetics and bioequivalence of Risperidone formulations after administration of single doses to normal, healthy subjects under fed conditions.
Interventions
- DRUG Risperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-10 |
| Est. Completion | 2005-01 |
| Phase | NA |
What the finished NCT01222923 record still lists
NCT01222923 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Risperidone is the first listed.
NCT01222923 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01222923 about?
NCT01222923 is a clinical study titled "Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fed Conditions". The purpose of this study is to determine the pharmacokinetics and bioequivalence of Risperidone formulations after administration of single doses to normal, healthy subjects under fed conditions.
What is the current status of trial NCT01222923?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2004-10. Estimated completion is 2005-01.
What interventions are being tested in trial NCT01222923?
The interventions under investigation include: Risperidone (DRUG).
Who is sponsoring clinical trial NCT01222923?
This trial is sponsored by Ranbaxy Laboratories Limited, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01222923's enrollment target sits among peer trials
40 1447th of 2000 higher than 465 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia